Simplify Logo
Orchard Therapeutics

Orchard Therapeutics

Autologous gene therapies for rare diseases.

Associate Director - Regulatory Science

Full-Time
$190k - $240k/yr
Expert
PharmD, PhD
Remote in USA
Remote

About the job

Requirements
  • Significant experience developing and executing United States regulatory strategies for industry development programs in Regulatory Affairs.
  • Knowledge and experience in the development or registration of biologics and/or Advanced Therapy Medicinal Products is desirable.
  • Very good knowledge and understanding of United States Code of Federal Regulations and Food and Drug Administration guidelines.
  • Experience using innovative United States expedited paths to approval in global development is desirable.
  • A track record of preparing, managing through Food and Drug Administration clearance, and maintaining Investigational New Drug applications.
  • Experience leading teams preparing for and attending major health-authority interactions, including pre-IND, End-of-Phase 1, and End-of-Phase 2 meetings.
  • Experience in regulatory submission project management.
  • A PharmD or PhD in a scientific discipline.
  • Strong attention to detail and the ability to produce high-quality regulatory documents.
  • Ability to establish and maintain collaborative working relationships within the Regulatory team and with other functions and stakeholders.
  • Ability to handle multiple tasks in parallel, plan and prioritize work, and respond effectively to program or activity changes.
  • Ability to develop partnerships that support a strong cross-functional and inclusive team environment.
  • Ability to work autonomously on allocated programs.
  • Excellent organizational, computer, and documentation skills.
  • A solution-oriented approach to problem-solving, including assessing variables, evaluating fundamental issues, anticipating business impact, and providing direction.
  • Strong interpersonal, verbal, and written communication skills
Responsibilities
  • Act as the United States regulatory lead on assigned programs.
  • Partner with Global Regulatory Leads and the Executive Director, Regulatory Science to provide regulatory inputs to cross-functional program teams.
  • Develop United States regulatory strategy, including innovative procedures to expedite the path to approval, in partnership with Global Regulatory Leads and program regulatory teams.
  • Identify regulatory risks, develop mitigation strategies, and support proactive agency engagement plans.
  • Support integrated regulatory planning across clinical, nonclinical, chemistry, and manufacturing functions.
  • Serve as the primary liaison with United States regulatory authorities for assigned programs.
  • Plan, prepare, and review submissions to the Food and Drug Administration, including Orphan Drug designation applications, Investigational New Drug applications, Fast Track or Regenerative Medicine Advanced Therapy designations, and pediatric study plans.
  • Prepare Food and Drug Administration meeting requests and briefing documents, coordinate cross-functional teams for meetings, and interface with United States regulatory authorities.
  • Coordinate and prepare responses to questions and requests for information from United States regulatory authorities.
  • Ensure regulatory documents are accurate, complete, compliant with applicable requirements, and prepared according to defined timelines.
  • Monitor, analyze, and disseminate intelligence on United States regulatory matters affecting development programs.
  • Lead implementation of new United States regulations and guidelines applicable to development programs in collaboration with Global Regulatory Leads and functional leads.
  • Contribute to updates, improvements, and development of regulatory processes, including new standard operating procedures.
  • Participate in internal audits and future health-authority inspections.
  • Share regulatory expertise and learning experiences within the regulatory team.
Desired Qualifications
  • Knowledge and experience in the development or registration of biologics and/or Advanced Therapy Medicinal Products.
  • Understanding of European Medicines Agency regulations and guidelines.
  • Previous experience using innovative United States expedited paths to approval in global development.
  • Previous experience preparing and submitting a Biologics License Application.
  • Regulatory Affairs certification.

About the company

Orchard Therapeutics develops autologous ex vivo gene therapies to treat rare, life-threatening genetic diseases. Its approach collects a patient’s hematopoietic stem cells, edits a functional gene outside the body, and reinserts the corrected cells to rebuild the blood and immune system. The company differentiates itself by delivering single-dose, patient-specific cures that aim to address the disease at its source, with Libmeldy/Lenmeldy as its approved product and a clinical-stage pipeline for other conditions. Orchard’s goal is to provide safe, one-time therapies for children with severe genetic disorders and to expand a portfolio of approved and investigational gene therapies through its Kyowa Kirin ownership.

Company Size

201-500

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

2015

Get referred to Orchard Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Kyowa Kirin’s February 3, 2026 £11 million UK investment funds Orchard’s development base.
  • OTL-203 finished enrollment nearly one year early on July 7, 2025, accelerating value inflection.
  • Lenmeldy reimbursement keeps expanding, including Beneluxa access and U.K. NHS availability.

What critics are saying

  • Revenue still hinges on Lenmeldy and Libmeldy; one launch failure cripples Kyowa Kirin’s rare-disease bet.
  • OTL-201 remains unapproved; a proof-of-concept stumble would freeze Orchard’s next-product story.
  • Bluebird, academic transplant centers, and newborn screening programs keep pressuring MLD adoption through 2027.

What makes Orchard Therapeutics unique

  • Libmeldy and Lenmeldy are the first approved ex vivo HSC gene therapies for early-onset MLD.
  • Orchard’s 2026 OTL-201 ILAP designation shows UK regulators still back its HSC platform.
  • OTL-203’s July 7, 2025 registrational trial beat standard allogeneic HSCT head-to-head.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

1%

2 year growth

2%
BioPharm International
Apr 8th, 2026
Orchard Therapeutics announces new gene therapy manufacturing facility.

Orchard Therapeutics announces new gene therapy manufacturing facility. A new facility in California will expand Orchard Therapeutic's capacity to develop and deliver lentiviral vector and gene-corrected hematopoetic stem cells. Orchard Therapeutics announced in a Dec. 13, 2018 press release that it signed a long-term lease agreement to build out a gene therapy manufacturing facility in Fremont, CA. The new 150,000-ft[2] facility adds to the Foster City and Menlo Park, CA sites, which oversee the ongoing development and validation of the manufacture of Orchard's ex vivo gene therapy product candidates. Once operational, the new site will provide cGMP manufacturing capacity for both lentiviral vector and cryopreserved cell therapy products, enhancing Orchard's ability to manufacture and deliver gene-corrected hematopoetic stem cells for a range of diseases on a global basis. In addition to this expanded capacity, the company also plans to continue its collaborations with its contract manufacturing partners. "The expansion of our California operations to now include a manufacturing facility is a critical step in advancing Orchard's capabilities to supply products for our ex vivo gene therapy programs," said Stewart Craig, chief manufacturing officer of Orchard Therapeutics, in the press release. "We believe that this new facility, as an early investment in our own manufacturing, will not only drive efficiencies and scalability in terms of lentiviral vector and drug product development, it will also complement the capabilities of our existing vector and drug product manufacturing partners to support the potential launch of our gene therapy clinical product candidates." The build-out of Orchard's new manufacturing facility is expected to begin in 2019, and the company expects to hire more than 100 full-time employees over the next few years to support in-house manufacturing efforts. Stay at the forefront of biopharmaceutical innovation - subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Marcom Globe Italy
Oct 7th, 2024
Orchard Therapeutics and Er-Kim Announce Partnership to Broaden Access to Libmeldy to Eligible Patients in Turkey and Certain Eurasian Countries

Er-Kim will collaborate with Orchard Therapeutics to refer eligible children with early-onset MLD identified in these countries to an established European-based qualified treatment center.

UnLimited Media
Mar 29th, 2024
French indie label body UPFI calls on French government to intervene in potential Warner Music Group takeover of Believe

Believe "embodies a model of success and resistance to the worrying phenomenon of consolidation at work in the sector that has seen the successive acquisition of many significant distributors", it adds, highlighting Sony Music's acquisition of The Orchard and AWAL.

BioSpace
Mar 19th, 2024
Orchard Wins Fda Approval For First Gene Therapy For Rare Pediatric Disease

Pictured: FDA signage at its headquarters in Maryland/iStock, hapabapaThe FDA on Monday approved Orchard Therapeutics’ autologous gene therapy atidarsagene autotemcel, which will now be marketed as Lenmeldy, for the treatment of metachromatic leukodystrophy in pediatric patients.Lenmeldy is the first authorized gene therapy for children with pre-symptomatic late infantile or early juvenile metachromatic leukodystrophy (MLD), according to the FDA’s press release on the approval. Lenmeldy is also the first approved therapy for early juvenile or early symptomatic forms of the disease.Orchard CEO Bobby Gaspar in a statement said that Lenmeldy’s approval “opens up tremendous new possibilities” for children suffering from these early-onset forms of MLD, “who previously had no treatment options beyond supportive and end-of-life care.”The company on Monday did not provide specific launch details for Lenmeldy but promises to do so within the week.MLD is a rare and heritable metabolic disease that affects one in every 100,000 live births. It is characterized by a pathological build-up of sulfatides in the brain, liver, kidneys, spleen and other body parts, which over time can cause organ damage and neurological issues. Those with MLD often suffer from motor, behavioral and cognitive problems, as well as seizures. Patients also slowly lose the ability to move, talk, swallow and eat.Children with MLD often degenerate to a vegetative state and require round-the-clock care. Most patients die within five years of disease onset.MLD is caused by a mutation in the arylsulfatase-A (ARSA) gene, which under healthy circumstances produces an enzyme that breaks down sulfatides

Ochre Digi Media Pvt Ltd.
Jan 26th, 2024
Orchard Therapeutics Enters Agreement with Beneluxa Consortium to Facilitate Reimbursed Access to Libmeldy

Orchard Therapeutics enters agreement with Beneluxa consortium to facilitate reimbursed access to Libmeldy.